@sandramcallister.bsky.socialLooking forward to World Medical Innovation Forum next week for Beyond the Blueprint | The Next Frontier of Precision Oncology.
We’ll discuss how precision oncology is evolving and where the next therapeutic opportunities may lie.
September 22 | 3:15 PM ET | Boston
@gmj-georgia.bsky.socialMolecular tumor boards—multidisciplinary teams that interpret tumor genomics—show clinical benefit in personalized cancer care. Bu… #Cancercareequity #Clinicaltranslation #Genomicmedicine #Moleculartumorboards #Precisiononcology #Cancercareequity #Clinicaltranslation #Genomicmedicine #Molecular…
@myesmo.bsky.social👉 #MAP2026 sessions (where speaker permission is granted) are now online for registered delegates & ESMO members via #OncologyPRO.
🔬 Watch on demand & keep up with the latest in #PrecisionOncology!
@gmj-georgia.bsky.socialNature Medicine has published an author correction for the ABBV-706 phase 1 trial, a SEZ6-targeting antibody-drug conjugate being tested in a… #ABBV706 #Antibodydrugconjugate #Phase1trial #Precisiononcology #Smallcelllungcancer #ABBV706 #Antibodydrugconjugate #Phase1trial #Precisiononcology #Sm…
@genesndiseases.bsky.socialLearn how DYRK kinases shape cancer therapy.
This review shows how DYRK proteins regulate #DNADamageResponse and highlights DYRK inhibitors as promising #PrecisionOncology strategies to exploit cancer-specific DNA repair vulnerabilities.
#GenesAndDiseases: doi.org/10.1016/j.ge...
@myesmo.bsky.social👏 Congratulations to the #ESMOMeritAward recipients at #MAP2026.
These young researchers are recognised for the scientific merit of their abstracts.
🔗 https://ow.ly/5XXJ50ZLf2y
#PrecisionOncology
@myesmo.bsky.social🙌 Welcome to #MAP2026
The #PrecisionOncology community is coming together in London for two days of science, exchange and collaboration.
From molecular diagnostics to clinical translation, join the conversations shaping the future of cancer care.
@myesmo.bsky.socialAbstracts are online for #MAP2026!
📍 London | 10–11 Sept
👉 From molecular insights to clinical impact, discover the research driving progress in #PrecisionOncology. Join leading experts in London for two days of science, innovation and collaboration.
@gmj-georgia.bsky.socialNature Medicine has published an author correction for the ABBV-706 phase 1 trial, a SEZ6-targeting antibody-drug conjugate being tested in a… #ABBV706 #Antibodydrugconjugate #Phase1trial #Precisiononcology #Smallcelllungcancer #ABBV706 #Antibodydrugconjugate #Phase1trial #Precisiononcology #Sm…